Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target

Bibliography

• Presta M, Dell’Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16(2):159-78
   PubMed Web of Science ®Google Scholar
• Zhang J, Li HT, Fang QC, et al. Role of fibroblast growth factor 19 in maintaining nutrient homeostasis and disease. Biomed Environ Sci 2014;27(5):319-24
   PubMed Web of Science ®Google Scholar
• Foltz IN, Hu S, King C, et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med 2012;4(162):162ra153
   PubMed Web of Science ®Google Scholar
• Nishimura T, Utsunomiya Y, Hoshikawa M, et al. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1999;1444(1):148-51
   PubMed Web of Science ®Google Scholar
• Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012;26(4):312-24
   PubMed Web of Science ®Google Scholar
• Asada M, Shinomiya M, Suzuki M, et al. Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim Biophys Acta 2009;1790(1):40-8
   PubMedGoogle Scholar
• Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003;17(13):1581-91
   PubMed Web of Science ®Google Scholar
• Kan M, Wu X, Wang F, et al. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem 1999;274(22):15947-52
   PubMedGoogle Scholar
• Kurosu H, Kuro OM. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2009;299(1):72-8
   PubMedGoogle Scholar
• Fon Tacer K, Bookout AL, Ding X, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010;24(10):2050-64
   PubMedGoogle Scholar
• Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2(4):217-25
   PubMed Web of Science ®Google Scholar
• Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003;72:137-74
   PubMed Web of Science ®Google Scholar
• Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006;68:159-91
   PubMed Web of Science ®Google Scholar
• Russell DW, Setchell KD. Bile acid biosynthesis. Biochemistry 1992;31(20):4737-49
   PubMedGoogle Scholar
• Lu TT, Makishima M, Repa JJ, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000;6(3):507-15
   PubMed Web of Science ®Google Scholar
• Choi M, Moschetta A, Bookout AL, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006;12(11):1253-5
   PubMed Web of Science ®Google Scholar
• Kir S, Kliewer SA, Mangelsdorf DJ. Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol 2011;76:139-44
   PubMedGoogle Scholar
• Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011;331(6024):1621-4
   PubMed Web of Science ®Google Scholar
• Lin BC, Wang M, Blackmore C, et al. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007;282(37):27277-84
   PubMedGoogle Scholar
• Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 2011;13(6):729-38
   PubMed Web of Science ®Google Scholar
• Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143(5):1741-7
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009;284(15):10023-33
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-63
   PubMed Web of Science ®Google Scholar
• Thomas G. The S6 kinase signaling pathway in the control of development and growth. Biol Res 2002;35(2):305-13
   PubMedGoogle Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8(3):235-53
   PubMed Web of Science ®Google Scholar
• Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA 2014;311(22):2315-25
   PubMed Web of Science ®Google Scholar
• Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 2011;19(3):347-58
   PubMed Web of Science ®Google Scholar
• Perry RJ, Samuel VT, Petersen KF, et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014;510(7503):84-91
   PubMed Web of Science ®Google Scholar
• Cicione C, Degirolamo C, Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology 2012;56(6):2404-11
   PubMed Web of Science ®Google Scholar
• Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 2008;8(3):224-36
   PubMed Web of Science ®Google Scholar
• Adams AC, Coskun T, Rovira AR, et al. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 2012;7(5):e38438
   PubMed Web of Science ®Google Scholar
• Alisi A, Manco M, Vania A, et al. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 2009;155(4):469-74
   PubMedGoogle Scholar
• Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7(4):195-203
   PubMed Web of Science ®Google Scholar
• Barutcuoglu B, Basol G, Cakir Y, et al. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 2011;41(4):390-6
   PubMed Web of Science ®Google Scholar
• Alisi A, Ceccarelli S, Panera N, et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One 2013;8(6):e67160
   PubMed Web of Science ®Google Scholar
• Eren F, Kurt R, Ermis F, et al. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem 2012;45(9):655-8
   PubMed Web of Science ®Google Scholar
• Wojcik M, Janus D, Dolezal-Oltarzewska K, et al. A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents. J Pediatr Endocrinol Metab 2012;25(11-12):1089-93
   PubMed Web of Science ®Google Scholar
• Schreuder TC, Marsman HA, Lenicek M, et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010;298(3):G440-5
   PubMed Web of Science ®Google Scholar
• Huang X, Yang C, Luo Y, et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007;56(10):2501-10
   PubMed Web of Science ®Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116(6):1413-19
   PubMed Web of Science ®Google Scholar
• Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38(7):485-9
   PubMedGoogle Scholar
• Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell 2003;115(7):787-98
   PubMed Web of Science ®Google Scholar
• Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008;48(6):1810-20
   PubMed Web of Science ®Google Scholar
• Fu T, Choi SE, Kim DH, et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho. Proc Natl Acad Sci USA 2012;109(40):16137-42
   PubMedGoogle Scholar
• Chen Q, Jiang Y, An Y, et al. Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease. Biochem Biophys Res Commun 2011;409(4):651-6
   PubMedGoogle Scholar
• Liu WY, Huang S, Shi KQ, et al. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. Expert Opin Ther Targets 2014;18:1305-13
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012;12:56
   PubMed Web of Science ®Google Scholar
• Chen Z, Xie B, Zhu Q, et al. FGFR4 and TGF-beta1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis. Int J Med Sci 2013;10(13):1868-75
   PubMedGoogle Scholar
• French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 2012;7(5):e36713
   PubMed Web of Science ®Google Scholar
• Poh W, Wong W, Ong H, et al. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer 2012;11:14
   PubMedGoogle Scholar
• Gauglhofer C, Paur J, Schrottmaier WC, et al. Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma. Carcinogenesis 2014;35(10):2331-8
   PubMedGoogle Scholar
• Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev 2014;34(2):280-300
   PubMed Web of Science ®Google Scholar
• Song P, Gao J, Inagaki Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer 2013;2(1):31-9
   PubMed Web of Science ®Google Scholar
• Kuhlmann WD, Peschke P. Hepatic progenitor cells, stem cells, and AFP expression in models of liver injury. Int J Exp Pathol 2006;87(5):343-59
   PubMed Web of Science ®Google Scholar
• Ho HK, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009;50(1):118-27
   PubMed Web of Science ®Google Scholar
• Chen L, Liu H, Liu J, et al. Klotho endows hepatoma cells with resistance to anoikis via VEGFR2/PAK1 activation in hepatocellular carcinoma. PLoS One 2013;8(3):e58413
   Google Scholar
• Hyeon J, Ahn S, Lee JJ, et al. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig Dis Sci 2013;58(7):1916-22
   PubMed Web of Science ®Google Scholar
• Chen YJ, Yeh SH, Chen JT, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000;119(2):431-40
   PubMed Web of Science ®Google Scholar
• Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25(2):181-200
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100(10):698-711
   PubMedGoogle Scholar
• Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140(5):1410-26
   PubMed Web of Science ®Google Scholar
• Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014;20(8):2072-9
   PubMed Web of Science ®Google Scholar
• Grosshans H, Filipowicz W. Molecular biology: the expanding world of small RNAs. Nature 2008;451(7177):414-16
   PubMedGoogle Scholar
• Xu YF, Yang XQ, Lu XF, et al. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun 2014;446(1):54-60
   PubMed Web of Science ®Google Scholar
• Luo Y, Yang C, Lu W, et al. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. J Biol Chem 2010;285(39):30069-78
   PubMedGoogle Scholar
• Lee S, Kang J, Cho M, et al. Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol 2009;34(1):161-72
   PubMed Web of Science ®Google Scholar
• Lopez-Serra L, Ballestar E, Ropero S, et al. Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene 2008;27(25):3556-66
   PubMedGoogle Scholar
• Wu X, Ge H, Lemon B, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010;285(8):5165-70
   PubMed Web of Science ®Google Scholar
• Kirstein MM, Vogel A. The pathogenesis of hepatocellular carcinoma. Dig Dis 2014;32(5):545-53
   PubMedGoogle Scholar
• Mellor HR. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations. Liver Int 2014;34(6):e1-9
   PubMed Web of Science ®Google Scholar
• Pai R, French D, Ma N, et al. Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol Sci 2012;126(2):446-56
   PubMed Web of Science ®Google Scholar
• Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 2005;129(5):1445-53
   PubMed Web of Science ®Google Scholar
• Berglund ED, Li CY, Bina HA, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009;150(9):4084-93
   PubMed Web of Science ®Google Scholar
• Fisher FM, Chui PC, Nasser IA, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 2014;147(5):1073-83
   PubMed Web of Science ®Google Scholar
• Miyata M, Sakaida Y, Matsuzawa H, et al. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. Biol Pharm Bull 2011;34(12):1885-9
   PubMedGoogle Scholar